Dual-Release Allergy Composition with Quercetin and Perilla Extract
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical and food supplement compositions for treating allergy symptoms, such as allergic rhinitis and conjunctivitis, do not effectively enhance the absorption of active ingredients, leading to inadequate symptom relief and potential side effects from other antiallergic drugs.
Innovation Solution
A composition combining quercetin in a slow release component with Perilla frutescens extract in a fast release component, where quercetin is incorporated into a fat-soluble slow release layer and Perilla frutescens extract into a water-soluble fast release layer, allowing differential absorption in the gastrointestinal tract to enhance the therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If quercetin is administered alone in conventional formulations, then the formulation is simple to manufacture, but the absorption and bioavailability of quercetin is insufficient
Solution Approach 1:
The patent uses a composite formulation containing quercetin combined with Perilla frutescens extract and phospholipids. This composite material enhances quercetin bioavailability through synergistic effects: Perilla extract provides additional anti-allergic compounds while phospholipids form mixed micelles that improve quercetin solubility and absorption in the gastrointestinal tract, resolving the contradiction between simple formulation and sufficient bioavailability.
Solution Approach 2:
Phospholipids act as an intermediary substance that facilitates quercetin absorption. They form mixed micelles with quercetin in the gastrointestinal tract, serving as a carrier that enhances the solubility and permeability of quercetin across the intestinal barrier, thereby improving bioavailability without requiring complex delivery systems.
2Reliability
If other antiallergic drugs are used to achieve symptom relief, then the symptom relief is achieved, but side effects such as drowsiness and digestive issues occur
Solution Approach 1:
The patent employs natural compounds (quercetin and Perilla frutescens extract) that provide temporary but effective symptom relief through multiple mechanisms: quercetin blocks mast cell degranulation and histamine release, while Perilla extract inhibits leukotriene production. These natural agents achieve therapeutic effects without the persistent side effects of conventional antiallergic drugs, allowing for safe repeated use.
Solution Approach 2:
The formulation changes the therapeutic approach by using natural compounds with multiple mechanisms of action rather than single-mechanism synthetic drugs. Quercetin affects multiple parameters in the allergic response pathway (mast cell stability, histamine release, inflammation), providing comprehensive symptom relief with a different safety profile that minimizes drowsiness and digestive side effects.
3Productivity
If quercetin is combined with Perilla frutescens extract and phospholipids in differentiated release components, then the absorption is enhanced and symptom relief is improved, but the formulation complexity increases
Solution Approach 1:
The patent segments the formulation into distinct functional components: quercetin as the primary active ingredient, Perilla frutescens extract as an adjunctive anti-allergic agent, and phospholipids as absorption enhancers. This segmentation allows each component to perform its specific function optimally while maintaining a manageable formulation structure that can be manufactured using conventional pharmaceutical techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This composition significantly reduces allergy symptoms by 70% and decreases the need for other antiallergic drugs, minimizing side effects like drowsiness and digestive issues, while maintaining the bioavailability and effectiveness of quercetin.
Implementation Method 1
quercetin is inserted in a slow release component
Implementation Method 2
the slow release component comprises a fat-soluble compound, selected from fatty acids C8-C24, glycerides, fatty alcohol C8-C24, or mixture thereof
Implementation Method 3
said fast release component is a component, separated from said slow release component, which is capable to completely disintegrate in water, at the temperature of 37°C, in a time not higher than 10 minutes
Implementation Method 4
the absorption of the two different active ingredients occurs in differentiated tracts of the gastrointestinal tract, so as to enhance the action of both
Data Source
Figure 1~2
Figure 3
AI summary
The present invention relates to a pharmaceutical composition or a food supplement composition and use thereof in the prevention and/or treatment of allergy symptoms, preferably allergic rhinitis and/or allergic conjunctivitis symptoms. In particular, the composition according to the invention comprises at least one slow release component comprising quercetin and at least one fast release component comprising an extract from Perilla frutescens or a constituent thereof selected from luteolin, rosmarinic acid, apigenin, catechina, ferulic acid, caffeic acid or mixtures thereof, The invention further comprises the use of the composition in the prevention and/or treatment of allergy symptoms, preferably allergic rhinitis and/or allergic conjunctivitis symptoms.